Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Australian vets treat anteater for ant allergy
Ants are an echidna’s main source of food.
Echidna in recovery after receiving allergen-specific vaccine

Vets and keepers at a zoo in Australia are celebrating after successfully treating an echidna who was found to be allergic to ants.

Ants are an echidna’s main source of food, so staff at Healesville Sanctuary, Victoria, were surprised when one of their spiny residents had an unusual reaction to them.

The echidna, named Matilda, was first presented to the sanctuary in 2010 after she was accidentally dug up from her burrow. Thought to be around three months old, she would have just started eating termites and ants.

Keepers became surrogates to Matilda as she had not been weaned, and she soon settled into her new environment. But at two years old, the skin around her eyes started to look a little inflamed.

The keepers provided topical treatments and cleaned the eyes but, after a noticeable spread of the inflammation, Matilda was transferred to the Melbourne Veterinary Specialist Centre for allergy testing.

To determine the cause of the inflammation, specialists injected a range of know antigens under Matilda’s skin and observed her for reactions. Once ants were identified as the cause, specialists got to work on developing an allergen-specific vaccine that was unique to her. She then underwent a period of ‘desensitisation’.

‘Matilda’s treatment plan required her vaccine to be given in small, regular doses, exposing her to enough of the allergen to cause an immune response but not so much that it would cause an adverse reaction,’ a spokesperson for Healesville Sanctuary explains. ‘In short, Matilda’s immune system was being trained to learn how to manage and respond to the identified allergens.

‘While time-consuming, this process of desensitisation has been highly effective and become a lifelong solution for Matilda’s allergies.’

Matilda responded well to the treatment and has now been vaccine-free for six months. Thought to be the world’s first allergic echidna, keepers are optimistic that she will now go on to live a long and allergy-free life.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.